[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054140":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":31,"locations":40,"responsibleParty":281,"collaborators":11,"id":283,"slug":284,"hasResults":285,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":11,"eligibilityCriteria":289,"healthyVolunteers":285,"sex":290,"minAge":291,"maxAge":11,"enrollmentInfo":292,"targetDuration":11,"studyType":295,"phases":296,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":319},{"fullName":5,"class":6},"Verastem, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"VS-7375 Monotherapy","EXPERIMENTAL",null,[13],"Drug: VS-7375",{"label":15,"type":10,"description":11,"interventionNames":16},"VS-7375 + cetuximab 2L PDAC",[13,17],"Drug: cetuximab",{"label":19,"type":10,"description":11,"interventionNames":20},"VS-7375 + cetuximab 1L PDAC",[13,17],[22,27],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","VS-7375","Taken by mouth",[19,15,9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"cetuximab","Subcutaneous infusion",[19,15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Verastem Call Center","CONTACT","7812924204","VS-7375-201TrialSupport@verastem.com",{"name":38,"role":34,"phone":11,"phoneExt":11,"email":39},"Luke Chung, MD","VS-7375-201Medical@verastem.com",[41,62,78,94,108,124,138,155,169,185,198,214,231,247,266],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"START- Los Angeles","RECRUITING","Los Angeles","California","90025","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-118.24368,34.05223,{"lat":53,"lon":52},[56,59],{"name":57,"role":34,"phone":11,"phoneExt":11,"email":58},"Hope Team","hopeteam@startresearch.com",{"name":60,"role":61,"phone":11,"phoneExt":11,"email":11},"Navid Hafez, MD","PRINCIPAL_INVESTIGATOR",{"facility":63,"status":43,"city":64,"state":65,"zip":66,"country":47,"countryCode":48,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":50,"coordinates":68},[69,70],-82.45843,27.94752,{"lat":70,"lon":69},[73,76],{"name":74,"role":34,"phone":11,"phoneExt":11,"email":75},"Brianna Holder","Brianna.Holder@moffitt.org",{"name":77,"role":61,"phone":11,"phoneExt":11,"email":11},"Dae-Won Kim, MD",{"facility":79,"status":43,"city":80,"state":81,"zip":82,"country":47,"countryCode":48,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Johns Hopkins University","Baltimore","Maryland","21287",{"type":50,"coordinates":84},[85,86],-76.61219,39.29038,{"lat":86,"lon":85},[89,92],{"name":90,"role":34,"phone":11,"phoneExt":11,"email":91},"Colleen Apostol","apostco@jhmi.edu",{"name":93,"role":61,"phone":11,"phoneExt":11,"email":11},"Mari Nakazawa, MD",{"facility":95,"status":43,"city":96,"state":97,"zip":98,"country":47,"countryCode":48,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"START Midwest","Grand Rapids","Michigan","49546",{"type":50,"coordinates":100},[101,102],-85.66809,42.96336,{"lat":102,"lon":101},[105,106],{"name":57,"role":34,"phone":11,"phoneExt":11,"email":58},{"name":107,"role":61,"phone":11,"phoneExt":11,"email":11},"Sreenivasa Chandana, MD",{"facility":109,"status":43,"city":110,"state":111,"zip":112,"country":47,"countryCode":48,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Washington University","St Louis","Missouri","63110",{"type":50,"coordinates":114},[115,116],-90.19789,38.62727,{"lat":116,"lon":115},[119,122],{"name":120,"role":34,"phone":11,"phoneExt":11,"email":121},"Olive Pressey","olive@wustl.edu",{"name":123,"role":61,"phone":11,"phoneExt":11,"email":11},"Kian-Huat Lim, MD",{"facility":125,"status":43,"city":126,"state":127,"zip":128,"country":47,"countryCode":48,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"START New Jersey","East Brunswick","New Jersey","08816",{"type":50,"coordinates":130},[131,132],-74.41598,40.42788,{"lat":132,"lon":131},[135,136],{"name":57,"role":34,"phone":11,"phoneExt":11,"email":58},{"name":137,"role":61,"phone":11,"phoneExt":11,"email":11},"Bruno Fang, MD",{"facility":139,"status":43,"city":140,"state":141,"zip":142,"country":47,"countryCode":48,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":50,"coordinates":144},[145,146],-86.78444,36.16589,{"lat":146,"lon":145},[149,153],{"name":150,"role":34,"phone":151,"phoneExt":11,"email":152},"Karlie Williams","6153297274","Karlie.Williams@scri.com",{"name":154,"role":61,"phone":11,"phoneExt":11,"email":11},"Meredith Pelster, MD",{"facility":156,"status":43,"city":157,"state":158,"zip":159,"country":47,"countryCode":48,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"START Dallas","Fort Worth","Texas","76104",{"type":50,"coordinates":161},[162,163],-97.32085,32.72541,{"lat":163,"lon":162},[166,167],{"name":57,"role":34,"phone":11,"phoneExt":11,"email":58},{"name":168,"role":61,"phone":11,"phoneExt":11,"email":11},"Salwan Almutar, MD",{"facility":170,"status":43,"city":171,"state":158,"zip":172,"country":47,"countryCode":48,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"MD Anderson Cancer Center","Houston","77054",{"type":50,"coordinates":174},[175,176],-95.36327,29.76328,{"lat":176,"lon":175},[179,183],{"name":180,"role":34,"phone":181,"phoneExt":11,"email":182},"Michelle Escano-Caballero","7137941776","MEscano@mdanderson.org",{"name":184,"role":61,"phone":11,"phoneExt":11,"email":11},"Shubham Pant, MD",{"facility":186,"status":43,"city":187,"state":158,"zip":188,"country":47,"countryCode":48,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"START- San Antonio","San Antonio","78229",{"type":50,"coordinates":190},[191,192],-98.49363,29.42412,{"lat":192,"lon":191},[195,196],{"name":57,"role":34,"phone":11,"phoneExt":11,"email":58},{"name":197,"role":61,"phone":11,"phoneExt":11,"email":11},"Drew Rasco, MD",{"facility":199,"status":43,"city":200,"state":201,"zip":202,"country":47,"countryCode":48,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"START- Mountain Region","West Valley City","Utah","84119",{"type":50,"coordinates":204},[205,206],-112.00105,40.69161,{"lat":206,"lon":205},[209,212],{"name":210,"role":34,"phone":11,"phoneExt":11,"email":211},"Julianna Daley","Julianna.daley@startresearch.com",{"name":213,"role":61,"phone":11,"phoneExt":11,"email":11},"William McKean, MD",{"facility":215,"status":43,"city":216,"state":217,"zip":218,"country":47,"countryCode":48,"cosmosGeoPoint":219,"geoPoint":223,"contacts":224},"UVA Health","Charlottesville","Virginia","22903",{"type":50,"coordinates":220},[221,222],-78.47668,38.02931,{"lat":222,"lon":221},[225,229],{"name":226,"role":34,"phone":227,"phoneExt":11,"email":228},"Clinical Trials Navigator","4349820539","UVACANCERTRIALS@uvahealth.org",{"name":230,"role":61,"phone":11,"phoneExt":11,"email":11},"Matthew Reilley, MD",{"facility":232,"status":43,"city":233,"state":217,"zip":234,"country":47,"countryCode":48,"cosmosGeoPoint":235,"geoPoint":239,"contacts":240},"Virginia Cancer Specialists","Fairfax","22031",{"type":50,"coordinates":236},[237,238],-77.30637,38.84622,{"lat":238,"lon":237},[241,245],{"name":242,"role":34,"phone":243,"phoneExt":11,"email":244},"Michelle Blair","4342437264","TNS8MW@uvahealth.org",{"name":246,"role":61,"phone":11,"phoneExt":11,"email":11},"Alexander Spira, MD",{"facility":248,"status":43,"city":249,"state":250,"zip":251,"country":252,"countryCode":253,"cosmosGeoPoint":254,"geoPoint":258,"contacts":259},"ICON Kurralta Park","Kurralta Park","South Australia","5037","Australia","AU",{"type":50,"coordinates":255},[256,257],138.56702,-34.95142,{"lat":257,"lon":256},[260,264],{"name":261,"role":34,"phone":262,"phoneExt":11,"email":263},"Sarah Gartland","08 84740420","Sarah.gartland@icon.team",{"name":265,"role":61,"phone":11,"phoneExt":11,"email":11},"Carolyn Bampton, MD",{"facility":267,"status":43,"city":268,"state":11,"zip":269,"country":252,"countryCode":253,"cosmosGeoPoint":270,"geoPoint":274,"contacts":275},"ICON Cancer Centre","South Brisbane","QLD 4101",{"type":50,"coordinates":271},[272,273],153.02049,-27.48034,{"lat":273,"lon":272},[276,279],{"name":277,"role":34,"phone":11,"phoneExt":11,"email":278},"Apryl Chelin","Apryl.chelin@icon.team",{"name":280,"role":61,"phone":11,"phoneExt":11,"email":11},"Jermaine Coward, MD",{"type":282,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100054140","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-pancreatic-cancer-100054140",false,"NCT07644559","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)","Inclusion Criteria:\n\n* Histopathology confirmed PDAC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n\nAdequate organ function\n\nVS-7375 + cetuximab (2L PDAC) :\n\n-Received only 1 prior Tx in the metastatic setting; prior adjuvant counts as a line if progressed within 6 months\n\nVS-7375 + cetuximab (1L PDAC) :\n\n-Treatment-naïve or received ≤ 1 cycle of SoC for metastatic disease\n\nExclusion criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose\n* History of drug-induced Interstitial Lung Disease\n* Receipt of prior direct RAS inhibitor\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":293,"type":294},180,"ESTIMATED","INTERVENTIONAL",[297],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer",[300,301],"Pancreatic Ductal Adenocarcinoma (PDAC)","G12D Mutated KRAS",[303,304,305,306,307,308,309],"KRAS G12D mutation","KRAS","PDAC","Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer","Pancreatic Neoplasms","RAS","2026-07-09",{"date":312,"type":313},"2026-07-13","ACTUAL",{"date":315,"type":313},"2026-06-16",{"date":317,"type":294},"2028-12",{"name":5,"class":6},15]